Motoyama AB / Proc Natl Acad Sci U S A / Chip-Man Technologies Ltd / T-DM1 / Im SA / Fleming / Norton / Hurvitz SA / Ettenberg SA / ChipMan Technologies Ltd / BioMed Central Ltd. / Creative Commons / /
Country
Finland / / /
Event
Product Issues / Product Release / FDA Phase / /
Facility
HER2T-DM1 complex / Laboratory of Molecular Oncology / HER2-T-DM1 complex / TDM1 complex / T-DM1 complex / University Central Hospital Haartmaninkatu / University of Helsinki / University of Tampere / /
IndustryTerm
cancer therapy / linkerdependent intracellular processing / treatment of HER2-positive breast cancer / treatment of breast cancer / treatment for early breast cancer / microtubule networks / treatment of metastatic breast cancer / treatment of advanced breast cancer / breast cancer treatment / treatment of trastuzumab-resistant breast cancer / /
MedicalCondition
HER2+ breast cancer / rapid tumor / tumor HER2 / clinical breast cancer / early breast cancer / primary human breast cancers / advanced breast cancer / breast cancer / lapatinib-resistant human breast cancer / residual tumor / tumor / locally advanced breast cancer / cancer / tumors / maytansine-resistant cancer / HER2-positive locally advanced breast cancer / incurable disease / primary tumor HER2 / breast and ovarian cancer / Low tumor HER2 / targeted cancer / HER2-positive breast cancers / stable disease / HER2positive breast cancer / trastuzumab-refractory metastatic breast cancer / HER2-positive breast cancer / HER2-positive metastatic breast cancer / primary tumor / HER2positive cancer / gastric cancer / patient tumors / trastuzumab-resistant gastric cancer / minimal tumor / HER2-normal cancer / human gastric cancer / lapatinib insensitive breast cancer / nausea / thrombocytopenia / J Cancer / frequent diarrhea / metastatic breast cancer / trastuzumab-sensitive breast cancer / macroscopic tumor / lapatinib-resistant breast cancer / MS / human breast cancer / MUC4-expressing breast cancer / cancers / preclinical breast cancer / disease / trastuzumab-resistant breast cancer / tumour / tumor PTEN / tumor necrosis / receptorpositive operable breast cancer / lapatinib cross-resistant breast cancer / trastuzumab resistant breast cancer / HER2-positive gastric cancer / trastuzumab-treated tumors / /
MedicalTreatment
endocrine therapy / cancer therapy / drug carriers / adjuvant chemotherapy / chemotherapy / Radioimmunotherapy / neoadjuvant treatment / /
Organization
University of Tampere / University of Helsinki / Laboratory of Molecular Oncology / Sequential administration / US Food and Drug Administration / /
Person
Jenny Chang / Rapid / Lewis Phillips / Serra V / /
Barok et al. Breast Cancer Research 2014, 16:209 http://breast-cancer-research.com/contentREVIEW Trastuzumab emtansine: mechanisms of action